Biolase Q2 EPS $(4.24) Beats $(5.33) Estimate, Sales $14.29M Miss $15.36M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biolase (NASDAQ:BIOL) reported Q2 losses of $(4.24) per share, beating the analyst consensus estimate of $(5.33) by 20.45 percent. However, the company's quarterly sales of $14.29 million missed the analyst consensus estimate of $15.36 million by 6.99 percent.
August 10, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biolase's Q2 earnings beat analyst estimates but sales fell short. This mixed result could lead to uncertainty in the market.
Biolase's Q2 earnings report is a mixed bag, with earnings beating estimates but sales missing. This could lead to uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100